Literature DB >> 15665401

Assembly of filamentous tau aggregates in human neuronal cells.

Li-Wen Ko1, Toni Rush, Naruhiko Sahara, Jay S Kersh, Colin Easson, Michael Deture, Wen-Lang Lin, Yamicia D Connor, Shu-Hui C Yen.   

Abstract

Intraneuronal deposition of microtubule-associated protein tau in filamentous aggregates constitutes a pathological hallmark of neurofibrillary degeneration that is characteristic of Alzheimer's disease (AD) and related disorders known collectively as tauopathies. Formation of such fibril inclusions, consisting of hyperphosphorylated tau in multiple isoforms, correlates with the severity of cognitive decline in AD. How neurofibrillary pathology evolves in tauopathy remains unclear at present, but availability of a cellular model with robust tau aggregation will permit experimental scrutiny of the mechanistic process leading to such neurodegeneration. Through the use of a serial transfection strategy in conjunction with a tau minigene construct, we succeeded in generating conditional transfectants of human neuronal lineage that overproduce wild-type human brain tau in isoforms 4R0N, 3R1N and 4R1N via TetOff and ecdysone inducible expression mechanisms. Such transgenic overexpression of tau in multiple isoforms facilitated the assembly of filamentous tau aggregates that exhibit immunoreactivities, physicochemical properties, and ultrastructural attributes reminiscent of those found in human tauopathies. The conditional tau transfectants thus provide us with a useful tool to elucidate the molecular and cellular events leading to neurofibrillary degeneration and a convenient means to test hypothetical mechanisms implicated in the etiopathogenesis of AD and related tauopathies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15665401     DOI: 10.3233/jad-2004-6605

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  10 in total

1.  Ethanol enhances tau accumulation in neuroblastoma cells that inducibly express tau.

Authors:  Tania F Gendron; Sharon McCartney; Ena Causevic; Li-Wen Ko; Shu-Hui Yen
Journal:  Neurosci Lett       Date:  2008-07-24       Impact factor: 3.046

2.  Rho-kinase ROCK inhibitors reduce oligomeric tau protein.

Authors:  Tadanori Hamano; Norimichi Shirafuji; Shu-Hui Yen; Hirotaka Yoshida; Nicholas M Kanaan; Kouji Hayashi; Masamichi Ikawa; Osamu Yamamura; Youshi Fujita; Masaru Kuriyama; Yasunari Nakamoto
Journal:  Neurobiol Aging       Date:  2019-12-16       Impact factor: 4.673

3.  Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease.

Authors:  Sudad Saman; WonHee Kim; Mario Raya; Yvonne Visnick; Suhad Miro; Sarmad Saman; Bruce Jackson; Ann C McKee; Victor E Alvarez; Norman C Y Lee; Garth F Hall
Journal:  J Biol Chem       Date:  2011-11-04       Impact factor: 5.157

4.  Cytosine beta-D-arabinofuranoside used as a paradigm modifier to increase production of tau aggregates in a cellular model of tauopathy.

Authors:  Li-Wen Ko; Jayanarayan G Kulathingal; Shu-Hui C Yen
Journal:  Neurochem Res       Date:  2006-12-06       Impact factor: 3.996

5.  Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells.

Authors:  Li-Wen Ko; Hwai-Hwa C Ko; Wen-Lang Lin; Jayanranyan G Kulathingal; Shu-Hui C Yen
Journal:  J Neuropathol Exp Neurol       Date:  2008-11       Impact factor: 3.685

6.  Phosphorylation regulates proteasomal-mediated degradation and solubility of TAR DNA binding protein-43 C-terminal fragments.

Authors:  Yong-Jie Zhang; Tania F Gendron; Ya-Fei Xu; Li-Wen Ko; Shu-Hui Yen; Leonard Petrucelli
Journal:  Mol Neurodegener       Date:  2010-08-30       Impact factor: 14.195

7.  Concentration-dependent effects of proteasomal inhibition on tau processing in a cellular model of tauopathy.

Authors:  Tadanori Hamano; Tania F Gendron; Li-Wen Ko; Shu-Hui Yen
Journal:  Int J Clin Exp Pathol       Date:  2009-06-15

8.  Homocysteine Increases Tau Phosphorylation, Truncation and Oligomerization.

Authors:  Norimichi Shirafuji; Tadanori Hamano; Shu-Hui Yen; Nicholas M Kanaan; Hirotaka Yoshida; Kouji Hayashi; Masamichi Ikawa; Osamu Yamamura; Masaru Kuriyama; Yasunari Nakamoto
Journal:  Int J Mol Sci       Date:  2018-03-17       Impact factor: 5.923

9.  Clioquinol Decreases Levels of Phosphorylated, Truncated, and Oligomerized Tau Protein.

Authors:  Gaoping Lin; Feiyan Zhu; Nicholas M Kanaan; Rei Asano; Norimichi Shirafuji; Hirohito Sasaki; Tomohisa Yamaguchi; Soichi Enomoto; Yoshinori Endo; Asako Ueno; Masamichi Ikawa; Kouji Hayashi; Osamu Yamamura; Shu-Hui Yen; Yasunari Nakamoto; Tadanori Hamano
Journal:  Int J Mol Sci       Date:  2021-11-08       Impact factor: 5.923

10.  Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy.

Authors:  Gen Matsumoto; Kazuki Matsumoto; Taeko Kimura; Tetsuya Suhara; Makoto Higuchi; Naruhiko Sahara; Nozomu Mori
Journal:  Int J Mol Sci       Date:  2018-05-17       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.